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Abstract Microbubbles are currently in clinical use as ultra-
sound contrast agents and under active investigation asmediators
of ultrasound therapy. To improve the theranostic potential of
microbubbles, nanoparticles can be attached to the bubble shell
for imaging, targeting and/or enhancement of acoustic response.
Existingmethods for fabricating particle-loaded bubbles, howev-
er, require the use of polymers, oil layers or chemical reactions
for particle incorporation; embed/attach the particles that can
reduce echogenicity; impair biocompatibility; and/or involve
multiple processing steps. Here, we describe a simple method
to embed nanoparticles in a phospholipid-coated microbubble
formulation that overcomes these limitations. Magnetic nanopar-
ticles are used to demonstrate the method with a range of differ-
ent microbubble formulations. The size distribution and yield of
microbubbles are shown to be unaffected by the addition of the
particles. We further show that the microbubbles can be retained
against flow using a permanent magnet, can be visualised by
both ultrasound and magnetic resonance imaging (MRI) and
can be used to transfect SH-SY5Y cells with fluorescent small
interfering RNA under the application of a magnetic field and
ultrasound field.
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Introduction
The first use of microbubbles as contrast agents for ultrasound
imaging dates back to the 1960s. However, early formulations
were unstable and difficult to reproduce. It was found that a
coating of albumin, initially derived from a patient’s own
blood, improved stability in vivo [1]. Since then, other types
of coating have been investigated, leading to a number of
commercial products including albumin-coated microbubbles
such as Albunex® and Optison® (GE Healthcare),
microbubbles formed from the dissolution of galactose crys-
tals and stabilised by palmitic acid such as Echovist® and
Levovist® (Schering AG) [2] and phospholipid-coated
microbubbles such as SonoVue® (Bracco), Sonazoid® (GE
Healthcare) and Definity® (Lantheus Medical Imaging) [3].
New agents are also being developed based on gas nanostruc-
tures formed by certain bacteria and archaea [4]. A number of
polymers have also been investigated for stabilising
microbubbles, for example polysaccharide alginate by
Wheatley et al. [5], arginine by Florinas et al. [6] and
poly(allylamine hydrochloride) grafted onto albumin by
Lentacker et al. [7]. Polymerisation of material around the
gas core produces a stiff bubble that has excellent stability
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but comparatively poor acoustic response; to date, there have
been no clinically approved polymer-based agents [5, 8].
Microbubbles are also being widely investigated for thera-
peutic applications. They can be used as nuclei to increase
cavitation activity [9] and/or as vehicles for drug delivery/
gene therapy by incorporation of therapeutic material which
can be subsequently released by destroying the microbubbles
with a high-amplitude ultrasound pulse [10–12]. The activity
of microbubbles produced by ultrasound exposure can im-
prove the penetration of a drug into a tissue volume [13–15]
and reversibly permeabilise cell membranes [16–19]. For ex-
ample, microbubbles have been shown to increase the uptake
of drugs such as paclitaxel and doxorubicin as well as colloi-
dal particles [11, 20, 21] and this is still a very active area of
research [22, 23].
Their ability to both improve ultrasound contrast and deliver
therapeutic molecules makesmicrobubbles excellent candidates
as theranostic agents. Their functionality can be further
enhanced through the incorporation or attachment of nanopar-
ticles to the microbubble shell. For example, superparamagnetic
iron oxide nanoparticles (SPIONs) that are used clinically as
MRI contrast agents [24, 25] can be used to enable both
multimodality imaging andmagnetic targeting ofmicrobubbles.
Gold nanoparticles can be attached to impart photoacoustic
contrast enhancement [26, 27]. Drugs can also be loaded onto
the microbubble shell in the form of particles [21].
Incorporating nanoparticles into polymer microbubbles
usually involves adding the nanoparticles during the forma-
tion of the microbubble so that they become embedded in the
polymer shell. For example, lysozyme and PVAmicrobubbles
have been created with gold nanoparticles embedded in their
surface via a pressurised gyration process for drug delivery
and biosensing [27]. Yang et al. prepared a microbubble con-
struct loaded with SPIONs for dual contrast imaging [28].
Park et al. have similarly produced stable microbubbles which
can attach different types of nanoparticles to their surface for
use in image contrast enhancement [29]. He et al. developed a
polymermagnetic microbubble forMRI with iron oxide nano-
particles on the surface of the microbubble which improved
the non-linear acoustic characteristics [30]. Duan et al. used a
synergistic approach of covalent coupling, electrostatic ad-
sorption and aggregation to attach nanoparticles to polymer
microbubbles for determination of optimum loading [31].
Self-assembled polymer microcapsules have also been devel-
oped via sonication of poly(allylamine) and poly(acrylic acid)
solution with citric acid-coated iron oxide nanoparticles for
dual-MRI and ultrasound contrast enhancement [32].
Kovalenko et al. developed hollow magnetic microspheres
using surfactant microbubbles and adsorbed cobalt ferrite
nanoparticles [33]. Silver nanoparticles have also been em-
bedded into polymer microbubble shells for dark field micros-
copy again by coating them with polymer and incorporating
them into the microbubble shell during the production process
[34]. Upconversion nanoparticles have also been attached to
the surface of microbubbles through a layer-by-layer approach
for fluorescence and ultrasound imaging [35].
Nanoparticles can be attached to phospholipid-coated
microbubbles via a variety of methods including biochemical
conjugation, electrostatic interaction or the addition of a hy-
drophobic carrier layer between the gas core and surfactant
coating. Mohamedi et al. [36] used a simple physical adsorp-
tion method in order to attach gold nanoparticles to the surface
of phospholipid-coated microbubbles. This was found to im-
prove the stability and non-linear acoustic response of the
microbubbles [36, 37]. Gold particles have also been attached
to microbubbles using chemically modified phospholipids,
e.g. by using a thiol linkage [38] or using avidin-coated gold
nanoparticles and biotinylated microbubbles, in both cases for
photoacoustic imaging [26, 39].
Phospholipid-coated magnetic microbubbles consisting of
a gas core surrounded by a layer of ferrofluid (liquid hydro-
carbon suspension of iron oxide nanoparticles) were success-
fully used for gene delivery by Stride et al. [40] and Mulvana
et al. [41]. The ferrofluid did, however, reduce the acoustic
responsiveness of the microbubbles, and there were some con-
cerns regarding the biocompatibility of the carrier liquid. In
2010, Mykhaylyk et al. [42] and Vlaskou et al. [43] published
a study on magnetically and acoustically active lipospheres.
Lipospheres differ from microbubbles as they contain a bilay-
er stabilised by a polar fluid rather than a monolayer at the
gas–water interface. The lipospheres were synthesised by me-
chanical agitation of a mixture of soybean oil, a cationic lipid,
magnetic nanoparticles, DNA, aqueous buffer and a
perfluoropropane gas in a sealed vial [43]. As therapeutic
delivery agents, the lipospheres did enable nucleic acid deliv-
ery under a magnetic field but the soybean oil again reduced
the acoustic responsiveness of the particles and there was no
increase in cell membrane permeability when ultrasound and a
magnetic field were applied [43]. Vlaskou et al. [43, 44] sub-
sequently investigated lipid shell microbubbles conjugated
with positively charged magnetic nanoparticles through elec-
trostatic interactions. These microbubbles had a much greater
response to ultrasound, and a combination of ultrasound and
magnetic forces improved transfection efficiency in vitro and
in vivo [44, 45]. Uncoated iron oxide nanoparticles have also
been attached to lipid microbubbles by vigorous shaking for
targeting magnetic stents, although the mechanism of incor-
poration in this study was not investigated in detail [46].
Magnetic nanoparticles have also been used in order to aug-
ment biomarker targeting. In 2011, magnetic microbubbles were
targeted via vascular cell adhesion molecule 1 (VCAM-1) for
molecular imaging and amagnetically targetedmicrobubble sys-
tem resulted in greater attachment to VCAM-1 in atherosclerotic
aortas in mice in conditions of high fluid shear stress. VCAM-1
was attached via avidin–biotin, and iron oxide nanoparticles
were also attached to the avidin bound to the bubble [47].
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Unfortunately, both electrostatic and biomimetic reactions,
such as avidin–biotin conjugation techniques, and hydropho-
bic layers also pose challenges in terms of their ultimate clin-
ical use. Charged particles have been shown to trigger un-
wanted immune responses [48], while avidin–biotin conjuga-
tion is time consuming with poor biocompatibility [49] and
hydrophobic layers can dampen the acoustic response of
microbubbles [41, 43]. The aim of this study was to develop
a method of incorporating nanoparticles into phospholipid








d i s t ea roy l - sn - g l yce ro -3 -phosphoe thano l amine -
N-(polyethylene glycol)-2000 (DSPE-PEG(2000)) and 1,2-
d i s t ea roy l - sn - g l yce ro -3 -phosphoe thano l amine -
N-[biotinyl(polyethylene glycol)-2000] (DSPE-PEG(2000)-
biotin) were purchased from Avanti Polar Lipids, Inc.
(Alabaster, AL, USA). Polyethylene glycol (PEG)-40 stearate,
ethanol, chloroform, Dulbecco’s phosphate-buffered saline,
foetal bovine serum, glycerol, propylene glycol, avidin, fluo-
rescein isothiocyanate (FITC) avidin, biotin and agarose pow-
der were purchased from Sigma-Aldrich Ltd. (Gillingham,
Dorset, UK). Phospholipid (phosphatidylcholine)-coated 50-
nm magnetite nanoparticles (FluidMAG-Lipid) were pur-
chased from Chemicell GmbH (Berlin, Germany). Sulphur
hexafluoride (SF6) was purchased from The BOC Group
(Guilford, Surrey, UK).
BLOCK-iT™ Fluorescent Oligo (Lot No. 1477937) was
purchased from Invitrogen (Life Technologies). This is a ge-
neric small interfering RNA (siRNA) with a fluorophore at-
tached that does not cause knockdown of a specific gene.
Phenol-free Dulbecco’s modified Eagle’s medium (DMEM)
and trypsin–EDTA (0.05%) phenol red were also purchased
from Life Technologies, Inchinnan Business Park, Paisley,
UK.
SH-SY5Y neuroblastoma cells (from ATCC from LGC
Standards, UK Office, Teddington, UK) were used as a model
cell line because of their rapid replication rate and ability to be
transfected using viral methods. Neuroblastoma is also one the
most common extracranial solid tumours in children with cer-
tain tumours expressing resistance to multimodal treatment
[50]; thus, the development of potential treatment methods is
highly desirable.
Bubble manufacturing technique
For the initial experiments, five different microbubble formu-
lations were utilised to test the versatility of the technique. For
each formulation, the lipids were dissolved in chloroform,
mixed in a glass vial at a selected molar ratio (Table 1), heated
to 50 °C and left for 12 h to evaporate the solvent. The
resulting lipid film was then suspended in aqueous solution
(2 ml at a concentration of 15 mg/ml) for ~1 h at 75 °C under
constant stirring as above. The stir bar was removed, and the
solution was then sonicated using an ultrasonic cell disruptor
(XL2000, probe diameter 3 mm; Misonix, Inc., Farmingdale,
NY, USA) operating at 22.5 kHz and level 4 corresponding to
8 WRMS output power, for 90 s, followed by sonication at the
gas–water interface (ensuring the probe tip touches the water
surface) under positive pressure of SF6 for 20 s at sonication
power 19 (38 WRMS). The microbubble solution was then
placed in an ice bath for cooling for approximately 10 min.
To prepare the magnetic microbubbles from each of the
formulations, after 60 s of sonication (power setting 4), a
suspension of (FluidMAG-Lipid) phosphatidylcholine-
coated magnetic nanoparticles in water (150 μl, 25 mg/ml)
was added. Sonication continued for a further 30 s followed
by sonication at the gas–water interface under a positive pres-
sure of SF6 for 20 s at power setting 19 as mentioned above.
Microbubble characterisation
Size distribution and concentration
Two methods were used for determining the size distribution
and concentration of the microbubble suspensions. The first
was single particle optical sizing (SPOS) using an AccuSizer
780 (NICOMP Particle Sizing Systems, Santa Barbara, CA,
USA) in which a 10 μl sample of each microbubble suspen-
sion was diluted in 50 ml of filtered deionised water in a flask
under mild mixing during measurement. The second was di-
rect observation under an optical microscope [51]. In the latter
method, 10 μl of the microbubble suspension was injected
into a haemocytometer. This was then observed using a
Leica DM500 optical microscope (Larch House, Milton
Keynes, MK14 6FG) with a ×40 objective lens at room tem-
perature. The bubble size distribution and concentration were
obtained using purpose written image analysis software in
MATLAB (2013b, The MathWorks, Natick, MA, USA).
The software converts each micrograph into a binary image,
and single circular shapes are then located, measured and
counted for each of the images analysed. A size distribution
and count are then produced for the microbubbles. In order to
obtain a representative size distribution for a single batch of
bubbles, at least 30 images from three separate bubble samples
must be analysed [51].
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Stability over time
Microbubble stability was determined by recording their size
distribution and concentration over 3 h using the second
method described above of direct observation under an op-
tical microscope and MATLAB image analysis. To enable a
comparison between formulations and different samples,
both the microbubble mean diameter and concentration were
non-dimensionalised with respect to the initial value at the
start of the experiment for each sample. Bubbles made from
the medium chain formulation with and without magnetic
nanoparticles were also characterised at both the ambient
and physiologically normal temperatures of 21 and 37 °C,
respectively.
Optical observation of magnetic response
A simple initial test was used to determine whether
microbubbles had been successfully functionalised with mag-
netic nanoparticles. An N45 NdFeB permanent magnet
(40 mm × 18 mm × 10 mm) with a magnetic field strength
of 0.365 T at a distance of 0.7 mm from the surface of the
magnetic pole was held at the surface of the vial containing the
microbubbles in order to observe whether or not microbubbles
would respond.
Transmission electron microscopy
The medium chain formulation was subjected to further,
more detailed characterisation. Transmission electron micros-
copy (TEM) was used to investigate the surface structure of
individual microbubbles and to confirm the incorporation of
nanoparticles [52]. Five microlitres of each microbubble sus-
pension was applied to a freshly glow-discharged carbon-
coated copper grid, and the grid was inverted for approxi-
mately 1 min in order to allow a high concentration of
microbubbles to remain in contact with the grid. The sample
was then negatively stained with 2% w/v uranyl acetate.
Samples were visualised at 80 kV with an FEI Tecnai™
T12 electron microscope. Low-dose images were acquired
at ~0.8 μm underfocus with 15e−/Å on a high-sensitivity
FEI Eagle 4096 × 4096 pixel CCD camera at a nominal
magnification of ×46,000 which corresponded to a sampling
size of 0.265 nm/pixel. On average, 10 microbubbles were
analysed for each sample. Microbubbles were excluded if
they appeared agglomerated such that one microbubble
could not be differentiated from another. No other objects
of the same size were observed in the suspensions.
Magnetic relaxivity
The magnetic relaxivity was also measured for the same
microbubble formulation as this provides an indication of
responsiveness to a magnetic field and potential utility as
an MRI contrast agent. Measurements were performed using
a 4.7 T Magnex or 7.0 T superconductive magnet driven by
a Varian DirectDrive™ spectrometer (Magnex Scientific and
Varian, Inc., subsidiaries of Agilent Technologies, Santa
Clara, CA, USA). A spin echo sequence was used to acquire
T2 and T1 maps. Single slice images were acquired with a
matrix size of 128 × 128 pixels in all cases, corresponding to
voxel dimensions of 0.4 × 0.4 × 5.0 mm. T2 maps were
generated from a series of spin echo images (repetition time
(TR) = 3.0 s) in which the echo time (TE) was logarithmi-
cally distributed in 10 steps from 9.7 to 100 ms. The total
experimental time was ~1 h. T1 maps were generated from a
series of inversion recovery spin echo images (TR = 10.0 s;
TE = 9.7 ms) in which the inversion recovery time was
logarithmically distributed in 10 steps from 10 ms to 6.0 s.
The total experimental time was ~3.5 h. The relaxation maps
were calculated using a standard mono-exponential fit
employing a least squares procedure.
Magnetic targeting under flow
To investigate magnetic targeting under flow, ultrasound im-
aging was used to observe the microbubbles. Details of the
apparatus are provided in the study of Owen et al. [53], but
briefly, a latex tube (3 mm inner diameter) was suspended in
a water bath at ambient temperature (23 °C) and connected
to a peristaltic pump (Gilson MiniPuls 3, Gilson, Luton,
Bedfordshire, UK) drawing from a reservoir of the relevant
suspending liquid. A section of the tube was positioned so
that it was parallel to the base of the bath with a gap of
approximately 3 cm to allow for the insertion of a magnetic
Halbach array consisting of five rectangular block N52 mag-
nets (10 mm × 10 mm × 25 mm, supplied by NeoTeXx,
Berlin, Germany) with transversal magnetisations (1.5 T)
Table 1 Different microbubble
formulations and the
corresponding molar ratio of
components used in the present
study
Name Components Molar ratio
(i) Short chain DPPC, PEG-40 stearate 9:1
(ii) Medium chain DSPC, PEG-40 stearate 9:1
(iii) Long chain DBPC, PEG-40 stearate 9:1
(iv) Charged DSPC, DSEPC, PEG-40 stearate 100:44:4.5
(v) Targeting DSPC, DSPE-PEG(2000), DSPE-PEG(2000)-biotin 82:9:9
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oriented at angles of 90° from one to the next in an alumin-
ium frame. A T junction was connected to the tubing to
allow for the injection of magnetic microbubbles upstream
of the magnet. The outlet of the tubing was fed to a waste
reservoir at atmospheric pressure (supplementary Fig. 1).
An ultrasound linear array transducer (9.4 MHz LA523,
Esaote, Italy) was positioned above the section of tube under
which the magnetic array was located in order to visualise the
microbubbles. Video sequences were acquired using an ULA-
OP ultrasound engine (Microelectronic System Design Lab.,
Universita degli Studi di Firenze, Firenze, Italy). The flow rate
was selected based on a previous study of magnetic targeting
of microbubbles against in vivo flow conditions [53]. Once a
steady flow had been established (0.25 ml/s) in the tube, data
were acquired for a few seconds to provide a baseline image
and a 1.5ml bolus ofmagneticmicrobubbles was then injected
and data were acquired for a further 60 s. This process was
repeated three times with and without a magnetic field applied.
Delivery of therapeutic compounds
Further tests were also performed to investigate the therapeutic
potential of magnetic microbubbles using the charged
microbubble formulation. For these tests, the charged bubble
formulation was used to facilitate attachment of siRNA.1 This
was based upon the work of Carson et al. [54], and the aimwas
to show the delivery capabilities of the microbubbles under
ultrasound and a magnetic field using an existing platform.
Zeta potential
Measurements of lipid vesicles and microbubbles (separately)
were performed via dynamic light scattering using a Zetasizer
Nano ZS, Malvern Instruments Ltd. (Worcestershire, UK) in a
disposable capillary cell (DTS1070) from Malvern
Instruments Ltd. (Worcestershire, UK). Each sample of the
vesicle or microbubble solution (60 μl) was added to 940 μl
of 10% HEPES buffer and measured using the Smoluchowski
protocol for up to 100 runs in order to produce an accurate zeta
potential measurement.
Attachment of siRNA
Twenty microlitres (7 μg) of fluorescently labelled siRNAwas
added to the lipid solution before sonication at the gas–water
interface. The solution was sonicated for 10 s followed by
sonication at the air–water interface under SF6 as described
previously. The solution was then washed by centrifugation
(300 relative centrifugal force (RCF), 10 min) in order to re-
move any excess siRNA [54]. This was then analysed via
fluorescence microscopy in order to determine whether the
siRNA had successfully attached to the microbubble surface.
The amount of siRNA that attached is based on the work of
Carson et al. [54] where it was determined that the maximum
amount of siRNA which can be attached to 1 × 109
microbubbles (approximately the number of microbubbles
per ml) is 7 μg. This was the quantity of siRNA added to the
bubble mixture and was equivalent to 7 × 10−9 μg of siRNA
per microbubble. The chargewas used to attach the siRNA and
was not desirable for use in vivo; however, it is currently the
optimal method for attachment of siRNA to the microbubble.
Cell culture
SH-SY5Y cells were examined for the delivery of fluorescent
siRNA. The cells were cultured in flasks using phenol-free
DMEM with FCS and antibiotics. When the cells were at
confluence, they were trypsinised, centrifuged and distributed
between OptiCell™ chambers (Thermo Fisher Scientific,
Bishop Meadow Road, Loughborough, UK) in phenol-free
DMEM. This resulted in a final concentration of 1.5 × 107
cells per OptiCell™. These were allowed to reach confluence
overnight in an incubator at 37 °C.
Ultrasound exposure
A schematic of the setup used for transfection experiments is
shown in Fig. 1. Ultrasound was generated using a circular
500-kHz focused ultrasound transducer (model H-107B-10;
Sonic Concepts, Inc., Bothell, WA, USA) featuring a rectan-
gular cutout through which a 128-element imaging array
(model L10-5; Zonare Medical Systems, Mountain View,
CA, USA) was aligned as described previously [55]. The
transducer was driven via two function generators (model
33250A; Agilent, Wokingham, Berkshire, UK)—the first
was set to pulse mode and triggered from the ultrasound plat-
form—and used to trigger the second which produced the
drive signal for the transducer. The use of two function gen-
erators thus allowed treatment to occur at a multiple of the
imaging frame rate as each imaging frame triggered a chain
of treatment pulses. The driving signal was applied to the
transducer via a 55-dB power amplifier (model A300;
Electronics and Innovation, Rochester, NY, USA) and imped-
ance matching network supplied by the transducer manufac-
turer. The free-field focal pressure and beam profile of the
transducer were calibrated in water using a 400-μm-diameter
needle hydrophone (model Onda 1056; Onda Corporation,
Sunnyvale, CA, USA). Pressure values referred to subse-
quently are peak negative focal pressures (PNFPs). The ultra-
sound platform (model Z-one; Zonare Medical Systems,
1 The purpose of these tests was to demonstrate the delivery potential of the
microbubbles. As mentioned in the BIntroduction^ section, the use of charged
bubbles may have disadvantages for in vivo use and an alternative coupling
strategy for the therapeutic molecule would be desirable. The development of
an alternative coupling strategy was, however, outside the scope of the present
study.
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Mountain View, CA, USA) was connected to a host desktop
PC to configure the system for passive acquisition and save
data after experiments.
The ultrasound transducer and imaging array assembly was
mounted on a three-axis positioning stage in a Perspex tank
filled with filtered, degassed, deionised water which was heat-
ed to 37 °C using an immersion heater. Prior to commencing
experiments, the focus of the transducer was located using a
200-μm needle hydrophone (Precision Acoustics, Dorchester,
UK) and the excitation voltage was adjusted to obtain the
peak-to-peak focal pressure required for experiments. The lo-
cation of the hydrophone tip observed under B-mode imaging
was recorded and used to position samples at the transducer
focus during experiments.
Samples were placed in a cell chamber (OptiCell™; Fisher
Scientific, Loughborough, UK) and mounted on top of the
Halbach array described above or a non-magnetic aluminium
bar of the same dimensions so that any reflections of the ultra-
sound field would be consistent between experiments. The
magnet and chamber assembly was then aligned with the focus
of the transducer under B-mode guidance. Based on previous
transfection experiments [40], the ultrasound conditions used
for treatment were 1 MPa peak-to-peak acoustic pressure,
40 cycles per burst and 1 kHz pulse repetition frequency for
10 s per treatment location. The ultrasound platform was set to
passively record the acoustic emissions from cavitation re-
ceived on the array during experiments at a frame rate of
50Hz for subsequent mapping and analysis as described below.
Immediately prior to each experiment, 1 ml of a siRNA-
loaded microbubble suspension or 1 ml PBS was added to
each cell chamber containing a confluent layer of cells on
one membrane in DMEM. Microbubbles were dispersed by
gentle agitation, and the chamber was placed in the water tank
with the cells on the lower surface so that only magnetic
microbubbles, upon application of a magnetic field, would
be attracted towards them. Each cell chamber was treated at
six evenly spaced locations as shown in Fig. 1. A total of five
cell chambers were treated using the conditions outlined in
Table 2.
Following treatment, the cell chambers were returned to
an incubator for approximately 1 h, after which the medium
containing microbubbles was removed. The chambers were
then washed with media (10 ml) and re-filled with further
media (15 ml) followed by analysis via fluorescence micros-
copy and an automatic plate reader (described below), which
was conducted on the same day as treatment.
Passive acoustic mapping
Following each experiment, the acoustic emissions captured
by the imaging array were mapped in space to provide an
estimate of the acoustic power of cavitation emissions using
the reconstruction algorithm described in [56]. Maps over a
10 × 20 mm area about the ultrasound focus were generated
for each frame of the received data. The sum of these maps
from each experiment was used to estimate the total energy
of acoustic emissions from each exposure and thus gives a
quantitative indication of cavitation activity occurring in
each sample.
Fig. 1 Setup for cell transfection
experiments (not to scale). A
cross-sectional view through the
water tank is shown. Samples
were placed in a cell chamber at
the focus of a 500-kHz focused
ultrasound transducer with a
rectangular cutout for an imaging
array. The imaging array was used
for B-mode imaging for
alignment of the sample at the
focus and to passively record
acoustic emissions during
ultrasound exposure. The
transducer was driven by a
function generator via a power
amplifier and impedance
matching network. A second
function generator set to generate
a pulse train was used to allow
treatment to take place at a
multiple of the imaging frame
rate. The black arrow points to an
OptiCell™ in the z-direction,
showing the six sites on the cell
culture plate that were exposed to
the conditions outlined below
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Fluorescence measurements
Fluorescence images were obtained on a Nikon Ti fluores-
cence microscope using the FITC filter settings. Bubbles
placed in an OptiCell™ were analysed in order to deter-
mine the conditions under which the fluorescent siRNA
could be observed. Cells were examined with the same
imaging settings (2 s exposure and gain of 1). Bright-field
images were also taken with an exposure time of 363 ms
and a gain of 1.
In each area exposed to ultrasound, bright-field (×10) and
FITC images were captured at the same location. A large
stitched image of 5 mm × 5 mm was obtained at each
insonation location in the OptiCell™. Each fluorescence im-
age was analysed in ImageJ in order to obtain an intensity
histogram. The maximum intensity in the image was then
recorded. For each OptiCell™, an average and a standard
deviation of the maximum intensities were determined. The
maximum intensity was chosen, owing to the chaotic nature of
cavitation-enhanced delivery and inhomogeneous distribution
over the insonation location. Differences in the average were
likely be small whereas the maximum in the OptiCell™where
transfection has been successful would likely be higher. The
average intensity for the whole OptiCell™ was obtained in a
Table 2 Summary of
experimental conditions for
transfection experiments
Label MMB (ml) Magnet (T) Ultrasound
OptiCell™ 1 1 – –
OptiCell™ 2 1 0.5 –
OptiCell™ 3 1 0.5 6 × (1 MPa p-p, 40 cycles, 1 kHz PRF, 10 s)
OptiCell™ 4 1 – 6 × (1 MPa p-p, 40 cycles, 1 kHz PRF, 10 s)
OptiCell™ 5 – – 6 × (1 MPa p-p, 40 cycles, 1 kHz PRF, 10 s)
MMB magnetic microbubbles with siRNA, p-p peak-to-peak (focal pressure), PRF pulse repetition frequency
Fig. 2 Proposed mechanism of
magnetic microbubble formation.
AA solution with lipid vesicles of
varying sizes and lipid-coated
nanoparticles is heated above the
phase transition temperature. B
During sonication at the gas–-
water interface, gas is entrained
forming bubbles and the lipid
vesicles break up into fragments
which adsorb onto the bubbles
with the nanoparticles. C After
cooling, the phospholipid shell
condenses with nanoparticles
entrapped within it
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BMG Labtech FLUOstar Omega plate reader and processed
using the FITC OptiCell™ setting. Each run took 14 min and
22 s. The fluorescence intensity of the whole OptiCell™ was
then analysed.
Results and discussion
We have shown in previous work using both fluorescence
microscopy and TEM that adsorption onto the microbubble
surface of nanoscale vesicles suspended in the liquid sur-
rounding the microbubbles may occur if the vesicle material
is chosen such that this process is thermodynamically
favourable [52]. This process is illustrated in Fig. 2. It was
therefore hypothesised that, through appropriate surface func-
tionalisation, nanoparticles could be incorporated into the
microbubble shell through a similar process during
microbubble formation. This would avoid the need for addi-
tional carrier layers or complex conjugation strategies and
should be applicable to a wide range of phospholipid formu-
lations and nanoparticles. For the purposes of this study,
superparamagnetic iron oxide was selected as a model nano-
particle since; as mentioned above, this can be used to facili-
tate both targeting and multimodality imaging.
Size distribution and concentration
Magnetic microbubbles were successfully produced with all
formulations. The results of the sizing and concentration mea-
surements are summarised in Table 3, and the representative
images are shown in Fig. 4. The average size (diameter) and
concentration did not appear to be adversely affected by the
addition of magnetic nanoparticles. The results showed that
the addition of magnetic nanoparticles had a minimal effect on
the modal average size (within the standard deviation) and
similar standard deviations were observed. Changes in con-
centration were also within the standard deviation for all sam-
ples with and without magnetic nanoparticles. Quantitatively
different results were obtained from the analysis of the micro-
scope images. However, this was not unexpected based on the
results of previous studies [51]. The minimum particle size
that can be accurately resolved by the AccuSizer is 0.5 μm,
whereas the resolution of a bright-field optical microscope
image is limited to ~1 μm. Thus, for populations containing
a high proportion of small bubbles (such as the medium and
long chain bubbles), the accuracy of the microscope measure-
ments will be reduced.
Bubble stability
Microbubble stability was assessed by examining changes in
size and concentration over time. The results for the medium
chain formulation with and without magnetic nanoparticles
are presented in Fig. 3. The addition of FluidMAG-Lipid
magnetic nanoparticles to microbubbles did not change the
stability of the formulation (differences were within the mea-
surement uncertainty). However, an increase in temperature to
37 °C led to a reduction in stability as would be expected. This
occurred for non-magnetic and magnetic microbubbles, indi-
cating magnetic nanoparticles do not adversely impact
microbubble stability.
Magnetic targeting
On application of a magnetic field, all the magnetic
microbubble formulations were observed to move towards
the magnet (Fig. 4d, e), indicating successful incorporation
of the nanoparticles.
Table 3 Average size and
concentration of all bubble
formulations with and without
magnetic nanoparticles from three
separate bubble samples obtained
via single particle optical sizing
(SPOS) and average size of all
bubble formulations via image





















0.90 1.31 1.73 0.46 1.65 1.32
Magnetic 1.24 1.92 1.47 0.32 1.56 1.21
Long chain 0.94 1.46 0.38 0.20 2.41 1.65
Magnetic 1.49 2.60 0.59 0.17 2.82 1.90
Short chain 2.92 2.11 0.68 0.23 2.41 1.04
Magnetic 3.86 2.88 0.46 0.14 3.57 1.59
Charged 3.73 3.24 0.41 0.08 2.97 1.87
Magnetic 2.75 2.37 0.70 0.16 2.63 1.52
Targeting 1.07 1.93 1.3 0.42 1.88 1.52
Magnetic 1.02 1.15 1.3 0.30 1.54 0.97
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Magnetic microbubbles were also injected into a latex
vessel under flow with and without a magnetic field applied
to a region of the tube in which the microbubbles were
imaged. Magnetic microbubbles flowed throughout the en-
tire vessel when no magnetic field was applied as shown in
Fig. 5a, b.
When a magnetic Halbach array was inserted beneath the
latex vessel, an increase in signal intensity was observed
along the wall of the vessel closest to the Halbach array
(Fig. 5d, e). In order to confirm magnetic targeting had
occurred, the videos were processed using MATLAB to
quantify the increase in intensity. When no magnetic field
was applied, the microbubbles moved to the top of the ves-
sel owing to buoyancy. The wall furthest from the Halbach
array thus showed a large increase in signal intensity as
shown in Fig. 5c. When the Halbach array was inserted,
the signal intensity at the wall closest to the magnet in-
creased, indicating that the microbubbles had responded to
the magnetic field (Fig. 5f). This test was based on a previ-
ous extensive study of magnetic targeting of microbubbles
and as such one flow condition was selected to test the
targeting ability against flow [53]. This indicates that
microbubbles incorporating magnetic nanoparticles in the
shell respond to a magnetic field and can target against the
flowing blood in the human body.
Magnetic relaxivity
Avibrating sample magnetometer (VSM) was used to confirm
tha t the mic robubb les were superpa ramagne t i c
(Supplementary Fig. 2). The results in Fig. 6 show that the
measured magnetic relaxivity of the microbubble formulation
was 0.9 × 106 bubbles/s. This result was performed on a sus-
pension that had been centrifuged (300 RCF, 10 min) to re-
move unbound magnetic nanoparticles. Based on the
relaxivity values for existing contrast agents, the results indi-
cate that the magnetic microbubble formulation would pro-
vide MRI contrast enhancement [57].
Transmission electron microscopy
Microbubbles were observed under electron microscopy
(Fig. 7a), allowing the nanoscale features of the shell to be
analysed. Clusters of lipid-coated nanoparticles were seen to
be incorporated into the shell (Fig. 7b). This, combined with
the magnetic response of the microbubbles, indicates that suf-
ficient quantities of nanoparticles were incorporated into the
microbubbles to facilitate targeting and/or MR imaging. The
nanoparticles have a nominal hydrodynamic diameter of
50 nm, but the geometric diameter appears to bemuch smaller,
approximately 20 nm. The nanoparticles were clustered at
discrete points within the shell. This appeared to cause addi-
tional discontinuities in the shell structure as compared to
microbubbles without nanoparticles observed by Owen and
Stride in previous work [52]. Some nanoscale vesicles that
did not contain iron oxide were also observed fused or em-
bedded in the microbubble surface (Fig. 7b). There are rela-
tively few nanoparticles visible in the images, which is sur-
prising given the magnetic response of the microbubbles
shown in Figs. 4, 5 and 6 above. However, the surface of the
shell can only be observed in two dimensions and so the
images may not provide an accurate indication of the number
of particles actually embedded within the shell. This informa-
tion provides direct evidence of magnetic nanoparticles incor-
porating into the microbubble shell. From the images, it is
possible to determine that there are approximately
167 ± 98 NPs/μm2 from measuring 10 microbubbles using
ImageJ. The total number of nanoparticles on each
microbubble can vary from 2000 to 9000 with bubble size
as the key determinant. However, it is likely that this is an
underestimate as the nanoparticle cluster at sites on the
microbubble and the clusters likely have depth in the shell
whereas the measurements obtained are only in 2D.
Fig. 3 Comparison of microbubble stability with and without iron oxide
nanoparticles. Normalised mean diameter and concentration data were
calculated for each time point by dividing the measurement result with
the initial measurement result at the start of the stability study. a Change
in mean diameter with time at 23 and 37 °C. b Change in concentration
with time at 23 and 37 °C. Error bars indicate the standard deviation
(n = 3)
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siRNA attachment
Fluorescence microscopy
Charged magnetic microbubbles sonicated with siRNA
followed by washing via centrifugation were seen to fluo-
resce, indicating successful incorporation of the siRNA. The
circular shape of the microbubbles could also be discerned in
the images as shown in Fig. 8a, b.
Zeta potential
As microbubbles are buoyant and will float during the zeta po-
tential measurements, this limits the amount of time over which
the measurement can be performed and reduces the accuracy of
the measurement. Lipid vesicles (microbubble precursors before
sonication at the gas–water interface) are neutrally buoyant and
can be measured more accurately for longer periods of time. As
microbubbles and vesicles were found to have the same zeta
potential, examination of siRNA attachment was performed on
vesicles. It was found that magnetic vesicles had a lower zeta
potential than non-magnetic vesicles. However, the zeta potential
was still positive, allowing negatively charged siRNA to bind to
it. Upon the addition of siRNA to the vesicle mixtures, the zeta
potential was found to have decreased. This occurred for mag-
netic and non-magnetic vesicles as shown in Fig. 8c, d. This
reduction in zeta potential indicated that siRNA had successfully
bound to the vesicle surface and that the magnetic nanoparticles
did not impair the attachment process. The fact that the zeta
potential remained positive suggests that the loading efficiency
may not have been maximised and that the quantity of DSEPC




In order to confirm whether or not siRNAwas taken up by the
cells, fluorescence microscopy images were obtained
(Supplementary Fig. 3E-H). All locations on each
OptiCell™ were analysed. A fluorescence intensity increase
was observed at all locations where magnetic microbubbles,
ultrasound and a magnetic field were applied. However, the
first two insonation locations showed the largest increase in
fluorescence intensity.
All the images obtained from each OptiCell™ were then
analysed for fluorescence intensity by ImageJ in order to
Fig. 4 Example of a microscope
image of a microbubbles
(medium chain) and b magnetic
microbubbles (at ×40
magnification, scale bar 50 μm
for both images). c Size
distribution of magnetic
microbubbles showing the
majority of microbubbles are
within the clinically relevant size
range <8 μm. A vial of magnetic
microbubbles d before and e after
application of a magnetic field is
also shown, with noticeable
accumulation of microbubbles in
proximity to the magnet
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obtain the maximum fluorescence for each image (Fig. 9a).
Only the combination of a magnetic field and ultrasound
showed a statistically significant difference in fluorescence.
The analysis of variance (ANOVA) statistical test was per-
formed giving a p value of <0.01. Using Tukey’s test, a sig-
nificant difference (p < 0.01) was observed between the group,
where a magnet and ultrasound (mag + US) were applied, and
all other groups.
Passive acoustic mapping
Acoustic maps showing the emissions from each of the
ultrasound-treated samples are shown in Supplementary
Fig. 4. In each sample, maps showing the distribution of
acoustic emissions are displayed with the six treatments per
sample arranged corresponding to their position in the
OptiCell™ and order of successive treatments shown by the
B
Fig. 5 Acoustic images of targeting of magnetic microbubbles. a Latex
tube with water flowing through. b After injection of magnetic
microbubbles. c Intensity analysis in the region of interest (ROI) along
the bottom wall (red) of the vessel and the top wall (blue) indicates the
highest signal intensity was detected at the top of the tube over the course
of the ultrasound. d The same latex tube with a magnetic Halbach array
positioned underneath with water flowing through. e After injection of
magnetic microbubbles, an increase in signal intensity is observed along
the bottom of the tube. f Intensity analysis within the same ROI along the
top (blue) and bottom (red) walls of the tube indicates that the highest
intensity occurred at the bottom of the tube at the wall closest to the
magnetic Halbach array
Fig. 6 Magnetic relaxivity of magnetic microbubble formulation created
with lipid-coated magnetic nanoparticles for three different
concentrations of microbubbles
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arrows. The focus of the transducer (and region in which cav-
itation is expected) is located approximately in the centre of
each map.
These data are summarised in Fig. 9b. In the sample with-
out magnetic microbubbles, cavitation energy was consistent-
ly low over the six exposures (mean 0.87 ± 0.02 μJ) due to the
lack of cavitation nuclei. In the sample with magnetic
microbubbles and ultrasound (without magnet), the energy
of cavita t ion increased by a factor of 25 (mean
22.2 ± 5.5 μJ). In the sample with magnetic microbubbles,
ultrasound and a magnetic field, the mean cavitation energy
increased by a further 70% (mean 38.0 ± 24.7 μJ) over the
non-magnet case, while the maximum energy of cavitation
more than doubled (67.7 vs. 30.9 μJ). Within each map, cav-
itation (where present) occurred at the expected location close
to the transducer focus. Comparing the six maps per sample
shows (Supplementary Fig. 4) that in the absence of magnetic
targeting, cavitation appears to be relatively evenly distributed
over the area of the chamber, while when the magnet was
added, cavitation was more localised. Cavitation in the loca-
tions treated first was of greater amplitude than that without
targeting and showed a pronounced decline on subsequent
exposures. These findings are in agreement with the fluores-
cence intensity data described above.
Fig. 8 Microscopy images of
magnetic microbubbles bound to
siRNA after centrifugation in a
bright field and b fluorescence
(10-s exposure, gain 1) using a
×20 objective. Scale bar is
50μm. cZeta potential of charged
microbubble precursors before
(red) and after (blue) the addition
of siRNA. d Zeta potential of
magnetically charged
microbubble precursors before
(red) and after (blue) the addition
of siRNA
Fig. 7 Transmission electron
microscopy images of
DSPC/PEG-40 stearate (9:1 M
ratio) microbubbles created with
lipid-coated nanoparticles. a The
whole structure and size of
magnetic microbubbles. b
Increased magnification of the
microbubble shell
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Plate reader results
After the OptiCell™ samples were exposed to the conditions
outlined above, they were analysed in the plate reader. The
data further support the microscopy images as OptiCell™ 3,
to which both ultrasound and a magnetic field were applied,
shows the highest fluorescence increase across the plate
(Supplementary Fig. 3A-D). The first two spots also show
the highest concentration of fluorescent material correspond-
ing to the passive acoustic mapping (PAM) data. However,
final spot 6, in the top left-hand corner (Supplementary
Fig. 2C), shows an increase in fluorescence which does not
correspond to an increase in acoustic activity. This was unex-
pected and is believed to be due to the first exposure, distrib-
uting siRNA over a wide area. However, this requires further
investigation. The plate reader results, combined with the
fluorescence microscopy and passive acoustic maps, indicate
that magnetically targeted microbubbles cavitating under ul-
trasound exposure delivered fluorescent siRNA to the cells in
the target area.
Concluding remarks
In this paper, a method for incorporating nanoparticles into
phospholipid microbubble formulations was presented. It
was shown that the method can be applied to a variety of lipid
bubble formulations with no additional processing steps re-
quired and that the particle-loaded microbubbles can be gen-
erated with a size distribution and stability appropriate for
intravenous administration. It was further shown that the mag-
netic microbubbles fabricated in this study could be targeted
against flow using a magnetic field, potentially utilised as
contrast agents for MRI and used to deliver siRNA to a cancer
cell line. This technique could be adapted for other lipid-
coated nanoparticles such as gold- or drug-encapsulating
particles without requirement for charge or biomimetic tech-
niques allowing easy adaptation of current clinically approved
phospholipid microbubbles. It could also provide more infor-
mation on the process of microbubble formation and the struc-
ture of the coating.
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